Hearing Aids Market to Surpass USD 13 Billion by 2031 Supported by AI-Powered Audio Technology and Rising Hearing Care Needs, Says Mordor Intelligence

Mordor Intelligence estimates the hearing aids market at USD 10.60 billion in 2026, forecasting growth to USD 13.34 billion by 2031 at a 4.72% CAGR. Demand is supported by aging populations, wider OTC access, and adoption of AI-enabled, rechargeable, and connected devices, while affordability and access to professional fitting remain constraints. North America is currently the largest regional market, and Asia-Pacific is identified as an emerging growth region.

Analysis

Treat the market-growth estimate as a low-conviction sector backdrop, not an earnings catalyst: it is a consultant forecast, not evidence of realized unit growth or pricing power. The key investment question is whether OTC brings incremental users into care or shifts sales from professionally fitted devices to lower-priced self-fit products. In the first case, Amplifon could benefit from assessment, fitting and follow-up referrals; in the second, retail conversion and service economics could weaken. For GN Store Nord, easier access may expand the addressable pool, but more direct-to-consumer competition could pressure device pricing and make brand, sound performance and fitting support more important than AI claims alone.

Over 1–3 months, look for company-specific evidence in hearing-device volumes, average selling prices, channel mix and gross-margin commentary; this report provides none. Over 6–18 months, AI features risk becoming table stakes as consumer-electronics ecosystems make connectivity easier to replicate. That could shift value toward distribution, fitting and ongoing support rather than hardware differentiation. Asia-Pacific may offer unit growth, but adoption does not automatically translate into attractive returns if affordability constrains prices or local distribution requires investment.

Contrarian read: broader OTC access is not unambiguously positive for incumbents. It can grow awareness and funnel complex cases to professionals, but it can also commoditize uncomplicated purchases. With no company-level data or valuation context, the market-growth forecast alone does not justify a directional position; the differentiated opportunity is to monitor channel economics rather than buy the category on narrative.

Key Decisions for Investors

• No immediate trade on the report. Keep GN and AMP on watch pending earnings evidence; do not infer company-specific revenue growth from the category forecast.
• For AMP, track store traffic, conversion, fitting/service attachment and same-store sales. A sustained decline in these alongside OTC growth would weaken the view that self-fit devices are a funnel into professional care.
• For GN, monitor hearing-device volume versus average selling price and margin commentary. Rising units accompanied by falling prices or weaker margins would indicate OTC-led substitution is outweighing market expansion.
• Reassess over the next 1–3 months as company updates arrive; a positive thesis needs evidence of incremental adoption without material price or service-mix erosion. Failure to show that would falsify the sector-growth trade.